Volume : 13, Issue : 04, April – 2026
Title:
DESIGN, CHARACTERIZATION AND IN VITRO EVALUATION OF AMIODARONE ENCAPSULATED SOLID LIPID NANOPARTICLES
Authors :
Kishore Bandarapalle*, Vadakaluri Sravani
Abstract :
The purpose of this study was to design; characterization and in vitro evaluation of Amiodarone encapsulated solid lipid nanoparticles. Amiodarone loaded SLN, was prepared by pre-emulsion followed by probe sonication method. Box- Behnken design was introduced to optimize the formulation of solid lipid nanoparticles Results: Fourier transform infrared spectroscopy studies indicate that no interaction or minor at molecular level suggest the excipients added were compatible with the drug. The value of zeta potential of optimized formulation of Amiodarone-SLN was found to be +75.9 mV which is sufficient to keep the particles stable. The optimized formulation has particle size of 233 ±3 nm and entrapment efficiency of 87.4 ± 1.29%, which were in good agreement with the predicted values. The scanning electron microscopy (SEM) analysis revealed distinct and mono-dispersed SLN with spherical shape.
Key words: Solid lipid nanoparticles, probe sonication method, Box-Behnken design & Fourier transform infrared spectroscopy.
Cite This Article:
Please cite this article in press Kishore Bandarapalle et al., Design, Characterization And In Vitro Evaluation Of Amiodarone Encapsulated Solid Lipid Nanoparticles., Indo Am. J. P. Sci, 2026; 13(04).
REFERENCES:
1. Xie S, Zhu L, Dong Z, Wang X, Wang Y, Li X, Zhou W. Preparation, characterization and pharmacokinetics of enrofloxacin-loaded solid lipid nanoparticles: influences of fatty acids. Colloids Surf B: Biointerfaces. 2011 Apr 1;83(2):382-7.
2. Chakraborty S, Shukla D, Mishra B, Singh S. Lipid–an emerging platform for oral delivery of drugs with poor bioavailability. Eur J Pharm Biopharm. 2009 Sep 1;73(1):1-5.
3. Luo Y, Chen D, Ren L, Zhao X, Qin J. Solid lipid nanoparticles for enhancing vinpocetine’s oral bioavailability. J Control Rel. 2006 Aug 10;114(1):53-9.
4. Xie S, Pan B, Wang M, Zhu L, Wang F, Dong Z, Wang X, Zhou W. Formulation, characterization and pharmacokinetics of praziquantel-loaded hydrogenated castor oil solid lipid nanoparticles. Nanomedicine. 2010 Jul;5(5):693-701.
5. Han C, Qi CM, Zhao BK, Cao J, Xie SY, Wang SL, Zhou WZ. Hydrogenated castor oil nanoparticles as carriers for the subcutaneous administration of tilmicosin: in vitro and in vivo studies. J Veter Pharmacol Ther. 2009 Apr;32(2):116-23.
6. Pandita D, Ahuja A, Lather V, Benjamin B, Dutta T, Velpandian T, Khar RK. Development of lipid-based nanoparticles for enhancing the oral bioavailability of paclitaxel. AAPS Pharmscitech. 2011 Jun 1;12(2):712-22.
7. Yuan H, Chen J, Du YZ, Hu FQ, Zeng S, Zhao HL. Studies on oral absorption of stearic acid SLN by a novel fluorometric method. Colloids Surf B: Biointerfaces. 2007 Aug 1;58(2):157-64.
8. Harde H, Das M, Jain S. Solid lipid nanoparticles: an oral bioavailability enhancer vehicle. Expert Opin Drug Deliv. 2011 Nov 1;8(11):1407-24.
9. Khan AA, Mudassir J, Mohtar N, Darwis Y. Advanced drug delivery to the lymphatic system: lipid-based nanoformulations. Int J Nanomed. 2013;8:2733.
10. Oussoren C, Zuidema J, Crommelin DJ, Storm G. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection.: II. Influence of liposomal size, lipid composition and lipid dose. Biochimica et Biophysica Acta- Biomembranes. 1997 Sep 4;1328(2):261-72.
11. Charman WN, Stella VJ. Estimating the maximal potential for intestinal lymphatic transport of lipophilic drug molecules. Int J Pharm. 1986 Dec 1;34(1-2):175-8.
12. Myers RA, Stella VJ. Factors affecting the lymphatic transport of penclomedine (NSC-338720), a lipophilic cytotoxic drug: comparison to DDT and hexachlorobenzene. Int J Pharm. 1992 Feb 25;80(1-3):51-62.
13. Lucks JS, Müller RH. Medication vehicles made of solid lipid particles (solid lipid nanospheres SLN). EP0000605497. 1991.
14. Trevaskis NL, Charman WN, Porter CJ. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Adv Drug Deliv Rev. 2008 Mar 17;60(6):702-16.
15. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev. 2001 Mar 23;47(1):65-81.
16. Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychutek K, Koch-Brandt C, Alyautdin R. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Targeting. 2002 Jan 1;10(4):317-25.
17. Lockman PR, Koziara JM, Mumper RJ, Allen DD. Nanoparticle surface charges alter blood–brain barrier integrity and permeability. J Drug Targeting. 2004 Dec 1;12(9-10):635-41.
18. Tosi G, Costantino L, Ruozi B, Forni F, Vandelli MA. Polymeric nanoparticles for the drug delivery to the central nervous system. Expert Opin Drug Deliv. 2008 Feb 1;5(2):155-74.
19. Hunter AC, Elsom J, Wibroe PP, Moghimi SM. Polymeric particulate technologies for oral drug delivery and targeting: a pathophysiological perspective. Maturitas. 2012 Sep 1;73(1):5-18.